Signaturefd, LLC Rhythm Pharmaceuticals, Inc. Transaction History

Signaturefd, LLC

$5.8 Billion
Q3 2025

A detailed history of Signaturefd, LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 232 shares of RYTM stock, worth $23,063. This represents 0.0% of its overall portfolio holdings.

Number of Shares

232

Previous 224 3.57%

Holding current value

$23,063

Previous $14,000 64.29%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 21, 2025	BUY	$65.14 - $104.57 $521 - $836	8 Added 3.57%	232 $23,000
Q1 2025 May 01, 2025	BUY	$48.56 - $61.02 $97 - $122	2 Added 0.9%	224 $11,000
Q4 2024 Feb 10, 2025	BUY	$46.91 - $67.33 $422 - $605	9 Added 4.23%	222 $12,000
Q4 2023 Jan 31, 2024	BUY	$21.39 - $49.64 $192 - $446	9 Added 4.41%	213 $9,000
Q3 2023 Nov 03, 2023	SELL	$15.81 - $27.8 $363 - $639	-23 Reduced 10.13%	204 $4,000
Q2 2023 Aug 01, 2023	BUY	$16.32 - $21.15 $375 - $486	23 Added 11.27%	227 $3,000
Q3 2022 Nov 08, 2022	BUY	$4.3 - $30.85 $877 - $6,293	204 New	204 $5,000
Q2 2022 Aug 10, 2022	SELL	$3.12 - $12.25 $215 - $845	-69 Closed	0 $0
Q1 2022 May 02, 2022	SELL	$6.13 - $12.24 $257 - $514	-42 Reduced 37.84%	69 $1,000
Q4 2021 Jan 25, 2022	SELL	$8.62 - $13.9 $15,972 - $25,756	-1,853 Reduced 94.35%	111 $1,000
Q3 2021 Oct 28, 2021	BUY	$11.68 - $20.72 $17,099 - $30,334	1,464 Added 292.8%	1,964 $26,000
Q2 2021 Jul 26, 2021	SELL	$18.52 - $22.55 $3,111 - $3,788	-168 Reduced 25.15%	500 $10,000
Q1 2021 Apr 30, 2021	BUY	$20.25 - $39.49 $13,527 - $26,379	668 New	668 $14,000
Q4 2020 Feb 11, 2021	SELL	$21.17 - $32.61 $4,234 - $6,522	-200 Closed	0 $0
Q3 2020 Nov 03, 2020	BUY	$18.13 - $30.61 $3,626 - $6,122	200 New	200 $4,000

Others Institutions Holding RYTM

# of Institutions

279

Shares Held

485M

Call Options Held

498K

Put Options Held

150K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $5.54B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account